IMI’s goal is to set innovation in motion. Research infrastructure that our projects leave behind includes not only physical structures, but any kind of resource or service that can be used by the wider research community, from equipment and materials to scientific data, communication networks, clinical networks and educational courses. Sustainable research infrastructures like these help reduce fragmentation and duplication of efforts in the innovation ecosystem.
From screening services for identifying new drug targets, to a bank of induced pluripotent stem cells, network of sites and labs, a plug-and-play vaccine-making platform, education programmes for patients and pharma professionals, and a non-profit entity to guide the use of health data system, the legacy of IMI-funded research will persist long after the consortia have disbanded.
For research projects to leave a legacy, long-term vision is vital
Drug safety academic programme expands to North America
A one-stop-shop for disease-specific human stem cells allows scientists to focus on research
Socio-economic legacy: EHR4CR's data reuse revolution
By linking up hospitals, the study of antibiotics in drug-resistant infections just got easier